These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 38411576)
41. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909 [TBL] [Abstract][Full Text] [Related]
42. Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor. Schmidt CJ; Moura LS; Dalcin PTR; Ziegler B J Bras Pneumol; 2024 May; 50(2):e20240107. PubMed ID: 38808835 [No Abstract] [Full Text] [Related]
43. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access. Hong E; Zampoli M; Beringer PM Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853 [No Abstract] [Full Text] [Related]
44. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis. Westhölter D; Haubold J; Welsner M; Salhöfer L; Wienker J; Sutharsan S; Straßburg S; Taube C; Umutlu L; Schaarschmidt BM; Koitka S; Zensen S; Forsting M; Nensa F; Hosch R; Opitz M Sci Rep; 2024 Apr; 14(1):9465. PubMed ID: 38658613 [TBL] [Abstract][Full Text] [Related]
45. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Mall MA; Mayer-Hamblett N; Rowe SM Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331 [TBL] [Abstract][Full Text] [Related]
46. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849 [No Abstract] [Full Text] [Related]
47. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis. Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261 [TBL] [Abstract][Full Text] [Related]
48. Elexacaftor/Ivacaftor/Tezacaftor: First Approval. Hoy SM Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874 [TBL] [Abstract][Full Text] [Related]
51. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393 [TBL] [Abstract][Full Text] [Related]
52. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis. McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711 [No Abstract] [Full Text] [Related]
53. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More Griese M; Costa S; Linnemann RW; Mall MA; McKone EF; Polineni D; Quon BS; Ringshausen FC; Taylor-Cousar JL; Withers NJ; Moskowitz SM; Daines CL Am J Respir Crit Care Med; 2021 Feb; 203(3):381-385. PubMed ID: 32969708 [No Abstract] [Full Text] [Related]
54. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880 [TBL] [Abstract][Full Text] [Related]
55. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610 [TBL] [Abstract][Full Text] [Related]
56. Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease. B B; A R; G R; A N; D G; S G; P F; M SG; L C; B G J Cyst Fibros; 2021 Sep; 20(5):768-771. PubMed ID: 34162524 [No Abstract] [Full Text] [Related]
57. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
58. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Hong E; Almond LM; Chung PS; Rao AP; Beringer PM Clin Pharmacol Ther; 2022 Jun; 111(6):1324-1333. PubMed ID: 35292968 [TBL] [Abstract][Full Text] [Related]